Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer

被引：12

作者：

Schwartzberg, Lee S. ^{[1
]}

Cobb, Patrick ^{[1
]}

Senecal, Frank ^{[1
]}

Henry, David ^{[1
]}

Kulig, Kimary ^{[2
]}

Walker, Mark S. ^{[1
]}

Houts, Arthur C. ^{[1
]}

Stepanski, Edward J. ^{[1
]}

机构：

[1] Accelerated Community Oncol Res Network, Memphis, TN 38138 USA

[2] Pfizer Global Outcomes Res, New York, NY 10017 USA

来源：

BREAST | 2009年 / 18卷 / 02期

关键词：

Switch/discontinue treatment; Tamoxifen; Aromatase inhibitor; Adverse events; Endocrine therapy; AROMATASE INHIBITORS; POSTMENOPAUSAL WOMEN; ANASTROZOLE; TAMOXIFEN; TRIAL; COMBINATION; SURVIVAL; RECEPTOR;

D O I：

10.1016/j.breast.2009.01.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials have shown that aromatase inhibitors (Als) are an important advance in the treatment of early stage breast cancer (ESBC), but practice patterns and the impact of treatment side effects of endocrine therapy in the community setting have not been extensively explored. This retrospective chart review describes practice patterns among patients receiving adjuvant endocrine therapy for ESBC. Charts of 200 patients with confirmed stage I-IIIA breast cancer were reviewed. Patients received first-line treatment with tamoxifen (n = 96) or Als (n = 104). Fifty-one patients completed a structured interview regarding symptom burden during therapy. Time to discontinuation or switching from first-line therapy did not vary by drug class (tamoxifen vs. Al). Musculoskeletal symptoms predicted time to switching among Al patients. Tamoxifen patients who switched to Als tended to do so following clinical guidelines for use of Als. Interview results showed that more anastrozole than tamoxifen patients cited side effects as the reason for switching. (C) 2009 Published by Elsevier Ltd.

引用

页码：78 / 83

页数：6

共 50 条

[1] Adjuvant endocrine Therapy in early stage Breast Cancer
Ruckhaberle, Eugen
Salmen, Jessica
Fehm, Tanja
[J]. GYNAKOLOGE, 2018, 51 (11): : 972 - 979
[2] Treatment With Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: Is It Forever?
Overmoyer, Beth
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) : 823 - +
[3] Scheduling the adjuvant endocrine therapy for early stage breast cancer
Kahruman, Sera
Ulusal, Elif
Butenko, Sergiy
Hicks, Illya V.
Diehl, Kathleen M.
[J]. ANNALS OF OPERATIONS RESEARCH, 2012, 196 (01) : 683 - 705
[4] Scheduling the adjuvant endocrine therapy for early stage breast cancer
Sera Kahruman
Elif Ulusal
Sergiy Butenko
Illya V. Hicks
Kathleen M. Diehl
[J]. Annals of Operations Research, 2012, 196 : 683 - 705
[5] Role of adjuvant endocrine therapy in early-stage breast cancer
Muss, HB
[J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 313 - 321
[6] Adjuvant endocrine therapy for early breast cancer
Andreetta, Claudia
Smith, Ian
[J]. CANCER LETTERS, 2007, 251 (01) : 17 - 27
[7] Selection of optimal adjuvant endocrine therapy for early-stage breast cancer
Al-Hajj A.
O'Regan R.
[J]. Current Treatment Options in Oncology, 2006, 7 (2) : 153 - 165
[8] Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
van Hellemond, Irene E. G.
Geurts, Sandra M. E.
Tjan-Heijnen, Vivianne C. G.
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (05)
[9] Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
Irene E. G. van Hellemond
Sandra M. E. Geurts
Vivianne C. G. Tjan-Heijnen
[J]. Current Treatment Options in Oncology, 2018, 19
[10] Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer
Corter, Arden L.
Broom, Reuben
Porter, David
Harvey, Vernon
Findlay, Michael
[J]. PSYCHO-ONCOLOGY, 2018, 27 (09) : 2096 - 2103

← 1 2 3 4 5 →